AIM RX 3pl, Llc Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: AIM RX 3pl, Llc Pharmaceutical Import Records from India — 4 Products, $13.4M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

AIM RX 3pl, Llc — Pharmaceutical Importer Profile (2026) | 4 Products, $13.4M Trade | TransData Nexus

AIM RX 3pl, Llc

Pharmaceutical Importer · United States · Analgesics & Antipyretics Focus · $13.4M Total Trade · DGFT Verified

AIM RX 3pl, Llc is a pharmaceutical importer based in United States with a total trade value of $13.4M across 4 products in 4 therapeutic categories. Based on 276 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. AIM RX 3pl, Llc sources from 1 verified Indian supplier, with Encube Ethicals Private Limited accounting for 100.0% of imports.

AIM RX 3pl, Llc — Import Portfolio & Supplier Network

AIM RX 3pl, Llc import network — 4 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to AIM RX 3pl, Llc?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Encube Ethicals Private Limited	$16.5M	500	100.0%

AIM RX 3pl, Llc sources from 1 verified Indian supplier across 248 distinct formulations. The sourcing is highly concentrated — Encube Ethicals Private Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does AIM RX 3pl, Llc Import?

Formulation	Value	Ships
Diclofenac sodium topical gel 1% lami	$3.7M	81
Clobetasol propionate ointment 0.05	$1.1M	32
Clobetasol propionate cream 0.05% 60g	$572.1K	15
Clindamycin phosphate top. lot.1% 60ML	$336.6K	9
Clobetasol propionate cream 0.05% 45g	$238.1K	8
Triamcinolone acetonide ointment USP	$203.2K	6
Clindamycin phosphate topical solution	$194.7K	7
Fluocinolone acetonide topical	$188.5K	7
Clindamycin (phosphate) gel 1% 30GM	$156.8K	4
Clindamycin (phosphate) gel 1% 60GM	$136.7K	4
Permethrin cream 5% 60GM batch no.3bw33,3bw35, 3bw34 mfg dec 2023 exp dt.nov	$134.5K	3
Fluocinonide topical solution 0.05% 60	$131.9K	5
Ketoconazole cream 2%, 30GM (batch no.	$115.7K	3
Product code : fg0002 clindamycin phosphate topical solution USP,1% 60ML b.no.4bh22 to 4bh25 mfg date mar 2024 exp	$111.8K	6
Clobetasol propionate cream 0.05% 30g	$108.6K	4

Import Portfolio — Top 4 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Diclofenac	Analgesics & Antipyretics	$4.1M	82	1.1%	8
2	Sodium	Nutritional Supplements	$3.6M	73	1.0%	10
3	Clindamycin	Antibiotics	$3.3M	73	3.6%	7
4	Ketoconazole	Antifungals	$2.4M	48	4.8%	3

AIM RX 3pl, Llc imports 4 pharmaceutical products across 4 categories into United States totaling $13.4M.

AIM RX 3pl, Llc — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

AIM RX 3pl, LLC is a pharmaceutical importer and buyer based in East Brunswick, New Jersey, United States. The company specializes in sourcing finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, primarily from India. With a total import value of $13.4 million USD over 276 shipments from 2022 to 2026, AIM RX 3pl, LLC plays a significant role in the U.S. pharmaceutical distribution network. The company's operations are centered at 40F Cotters Lane, Suite 100, East Brunswick, NJ 08816.

AIM RX 3pl, LLC's primary supplier is ENCUBE ETHICALS PRIVATE LIMITED, accounting for 100% of its imports. This exclusive sourcing relationship indicates a strategic choice to maintain a consistent supply chain and product quality. The company's product portfolio is concentrated, with the top five products—Diclofenac Sodium, Clindamycin, Ketoconazole, and others—comprising 100% of its imports. This focus suggests a targeted approach to meet specific therapeutic needs in the U.S. market.

2Distribution Network

While specific details about AIM RX 3pl, LLC's warehouse locations and logistics capabilities are not publicly disclosed, the company's import activities indicate a well-established distribution network. The primary port of entry for shipments is Newark, New Jersey, with goods arriving from ports such as Nhava Sheva in India and Genoa in Italy. This suggests a streamlined logistics operation capable of handling international shipments efficiently.

The company's geographic coverage within the United States is not explicitly detailed in the available data. However, given its base in East Brunswick, NJ, and the importation of pharmaceutical products, it is likely that AIM RX 3pl, LLC serves various regions across the U.S., supplying pharmaceutical products to wholesalers, hospitals, and possibly retail pharmacies.

3Industry Role

AIM RX 3pl, LLC functions as a pharmaceutical importer and buyer, sourcing finished pharmaceutical formulations from international suppliers, primarily ENCUBE ETHICALS PRIVATE LIMITED in India. The company's role in the U.S. pharmaceutical supply chain is that of a logistics intermediary, facilitating the importation and distribution of pharmaceutical products to various stakeholders within the industry. By focusing on sourcing specific therapeutic products, AIM RX 3pl, LLC contributes to the availability and diversity of pharmaceutical options in the U.S. market.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — AIM RX 3pl, Llc

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

AIM RX 3pl, LLC's sourcing strategy is highly concentrated, with ENCUBE ETHICALS PRIVATE LIMITED being the sole supplier for all its imported products. This single-source dependency can be viewed as both a risk and a strategic choice. On one hand, it allows for streamlined operations and potentially better pricing and quality control. On the other hand, it exposes the company to supply chain disruptions if issues arise with the sole supplier.

The shipment data reveals a consistent and stable relationship between AIM RX 3pl, LLC and ENCUBE ETHICALS PRIVATE LIMITED, with regular shipments over the years. This stability indicates a well-established partnership, reducing the risk associated with single-source dependency. However, the lack of diversification in suppliers means that any disruption with ENCUBE ETHICALS PRIVATE LIMITED could significantly impact AIM RX 3pl, LLC's operations.

2Supply Chain Resilience

AIM RX 3pl, LLC's supply chain resilience is closely tied to its exclusive relationship with ENCUBE ETHICALS PRIVATE LIMITED. The company's import data indicates a consistent flow of shipments, suggesting a reliable supply chain. However, the absence of backup suppliers means that any disruption with ENCUBE ETHICALS PRIVATE LIMITED could pose challenges.

The diversity of formulations imported—248 unique formulations—indicates a broad product range, which can help mitigate risks associated with single-product dependency. Shipping route exposure is primarily to ports in India and Italy, which are well-established and have robust infrastructure, potentially reducing logistical risks. The regulatory compliance of ENCUBE ETHICALS PRIVATE LIMITED is crucial; as an Indian supplier, it must adhere to international standards recognized by regulatory bodies such as the U.S. Food and Drug Administration (FDA) and the World Health Organization (WHO).

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) is the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces regulations to ensure that imported drugs meet safety, efficacy, and quality standards. Key legislation governing pharmaceutical imports includes the Federal Food, Drug, and Cosmetic Act, which outlines the requirements for drug approval, labeling, and manufacturing practices.

The marketing authorization pathway for Indian generics involves several steps:

1. Abbreviated New Drug Application (ANDA): Indian manufacturers must submit an ANDA to the FDA, demonstrating that their generic product is bioequivalent to the reference listed drug.

2. Good Manufacturing Practice (GMP) Compliance: Manufacturers must comply with FDA's GMP regulations, ensuring that products are consistently produced and controlled.

3. Inspection and Approval: The FDA conducts inspections of manufacturing facilities to verify compliance with GMP and other regulatory requirements.

4. Labeling Requirements: Products must have labeling that meets FDA standards, including accurate information about the drug's use, dosage, and potential side effects.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products in the United States are stringent. Importers must ensure that all imported drugs are approved by the FDA and comply with U.S. regulations. This includes verifying that the foreign manufacturer holds an FDA registration and that the product has an approved ANDA.

AIM RX 3pl, Llc — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

AIM RX 3pl, LLC's product category focus on Analgesics & Antipyretics, Nutritional Supplements, and Antibiotics aligns with prevalent therapeutic needs in the U.S. market. The significant import values in these categories—$4.1 million for Diclofenac Sodium, $3.6 million for Clindamycin, and $2.4 million for Ketoconazole—indicate strong market demand. This strategic focus allows the company to cater to critical healthcare needs, positioning itself as a key player in these therapeutic areas.

2Sourcing Profile

AIM RX 3pl, LLC's sourcing strategy is centered on generic drugs, primarily importing finished formulations from India. The company's preference for specific formulations, such as Diclofenac Sodium, Clindamycin, and Ketoconazole, suggests a targeted approach to meet identified market demands.

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — AIM RX 3pl, Llc

What products does AIM RX 3pl, Llc import from India?

AIM RX 3pl, Llc imports 4 pharmaceutical products across 4 categories. Top imports: Diclofenac ($4.1M), Sodium ($3.6M), Clindamycin ($3.3M), Ketoconazole ($2.4M).

Who supplies pharmaceuticals to AIM RX 3pl, Llc from India?

AIM RX 3pl, Llc sources from 1 verified Indian suppliers. The primary supplier is Encube Ethicals Private Limited (100.0% of imports, $16.5M).

What is AIM RX 3pl, Llc's total pharmaceutical import value?

AIM RX 3pl, Llc's total pharmaceutical import value from India is $13.4M, based on 276 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does AIM RX 3pl, Llc focus on?

AIM RX 3pl, Llc imports across 4 categories. The largest: Analgesics & Antipyretics (30.6%), Nutritional Supplements (27.2%), Antibiotics (24.6%).

Get Full AIM RX 3pl, Llc Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.